Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 w » 5 wt (Expand Search)
Showing 121 - 140 results of 100,569 for search '(( 5 w decrease ) OR ( 5 ((ng decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.62s Refine Results
  1. 121
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 122
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 123
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 124
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 125
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 126
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 127
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 128
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 129
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 130
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 131
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 132
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 133
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 134
    LPS decreases only T cell proliferative response to OKT3.

    LPS decreases only T cell proliferative response to OKT3. by Fanny Poujol (834338)

    Published 2015
    Save to List
    Saved in:
  15. 135
    Six weeks of voluntary wheel running decreases 5-HT<sub>2C</sub> mRNA expression in the medial dorsal striatum.

    Six weeks of voluntary wheel running decreases 5-HT<sub>2C</sub> mRNA expression in the medial dorsal striatum. by Benjamin N. Greenwood (295216)

    Published 2013
    Save to List
    Saved in:
  16. 136
    Sudachitin decreases osteoclastogenesis induced by RANKL in cultures of osteoclast precursors.

    Sudachitin decreases osteoclastogenesis induced by RANKL in cultures of osteoclast precursors. by Yoko Ohyama (4775400)

    Published 2018
    Save to List
    Saved in:
  17. 137
    Overexpression of Lethe in RAW macrophage cells decreases ROS production.

    Overexpression of Lethe in RAW macrophage cells decreases ROS production. by Carlos Zgheib (311460)

    Published 2017
    Save to List
    Saved in:
  18. 138
    Poly (I:C) decreases HIV-1 replication in PBMCs.

    Poly (I:C) decreases HIV-1 replication in PBMCs. by Christiane Rollenhage (762318)

    Published 2015
    Save to List
    Saved in:
  19. 139
    Ara-C treatment caused a decrease in microglia, NG2+ progenitors, oligodendrocytes, astrocytes and T cells in the spinal cord of SOD1<sup>G93A</sup> mice.

    Ara-C treatment caused a decrease in microglia, NG2+ progenitors, oligodendrocytes, astrocytes and T cells in the spinal cord of SOD1<sup>G93A</sup> mice. by Jean-Nicolas Audet (326107)

    Published 2013
    Save to List
    Saved in:
  20. 140
    CMV infection decreases TER of polarized HCoEpiC.

    CMV infection decreases TER of polarized HCoEpiC. by Ekaterina Maidji (3797899)

    Published 2017
    Save to List
    Saved in:

Search Tools: